Physician profile
Dwight Im
NPI 1770521130
$93,305.68
in general payments reported to CMS, 2019-2025
25 companies · $1,912 in 2025
The $1,912 reported for 2025 was more than what 78% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $837 · 2021: $11K · 2022: $29K · 2023: $1,402 · 2024: $27K · 2025: $1,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Food and Beverage: $3,279 · Travel and Lodging: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,637.50 |
| Food and Beverage | $3,278.60 |
| Travel and Lodging | $843.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $35,250.38 | 2019-2025 | Da Vinci Surgical System |
| Baxter Healthcare | $28,461.30 | 2019-2025 | Tisseel, Floseal, Perclot |
| Momentis Surgical INC. | $10,321.23 | 2021-2022 | |
| Conmed Corporation | $10,200.10 | 2019 | |
| Ethicon INC. | $7,166.23 | 2019-2021 | |
| Ethicon US, LLC | $589.92 | 2019-2025 | Enseal, Enseal X1 |
| Stryker Corporation | $498.70 | 2019-2023 | Sonopet Iq |
| Integra Lifesciences Corporation | $239.47 | 2019 | |
| Caldera Medical, INC | $151.42 | 2025 | |
| Astellas Pharma US INC | $53.29 | 2024-2025 | Veozah |
| Dysis Medical, INC. | $48.21 | 2019 | |
| Merck Sharp & Dohme LLC | $46.63 | 2022-2023 | Keytruda, Lenvima |
| Clovis Oncology, INC. | $36.26 | 2019-2020 | |
| Abbvie INC. | $33.58 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $27.37 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $25.90 | 2021 | |
| Therapeuticsmd, INC. | $24.99 | 2019 | |
| Seagen INC. | $19.17 | 2022 | |
| Aesculap, INC. | $18.76 | 2019 | |
| Glaxosmithkline, LLC. | $18.35 | 2024 | Jemperli |
| Astrazeneca Pharmaceuticals Lp | $17.09 | 2019 | |
| Lupin INC. | $15.83 | 2019 | |
| Coopersurgical, INC. | $14.97 | 2019 | |
| Millicent US INC | $14.74 | 2024 | Intrarosa, Femring |
| Smith+Nephew, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Im listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.